Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (20266)	4/3/1999 5:29:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

FWIW, Just thought I would point out to potential new Vivus investors what I consider the most important change in Vivus Inc. Vivus has currently changed its focus from: "Business Summary Vivus, Inc. focuses on the design and development of products for the treatment of erectile dysfunction whose products include MUSE (alprostadil) and ACTIS." (Source: prior 10Q statements in 1998) to: "COMPANY OVERVIEW VIVUS, Inc. ("VIVUS" or the "Company"), is the developer and manufacturer of MUSE(R) (alprostadil) and ACTIS(TM), two advancements in the treatment of men with erectile dysfunction ("ED"), also known as impotence. The Company's objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders. The Company intends to market and sell its products through distribution, co-promotion or license agreements with corporate partners." (Source: 1998 10k form). I believe that as a longer term investor this is an important factor to note. Vivus has gone from a focus on products for "male erectile dysfunction" to a focus on "sexual dysfunction AND urological disorders". This makes Vivus a more diversified company since now anything in the urological field is fair game for Vivus' R&D plans. We already know that the female sexual dysfunction patent approval opens a rather important new door for new product development and significant earnings income for the longer run.